By Fineline Cube 
IMPACT Therapeutics, Inc. (HKG: 7630) announced an exclusive partnership with Pharmanovia for senaparib (brand name: Paishuning), a novel, highly active PARP1/2 inhibitor independently developed by IMPACT. The Marketing Authorization Application (MAA) for first‑line maintenance treatment of adult patients with advanced ovarian cancer in Europe was accepted by the European Medicines Agency (EMA) in August 2025, with approval expected in the second half of 2026.
Deal Overview
| Item | Detail |
|---|---|
| Companies | IMPACT Therapeutics, Inc. (HKG: 7630) / Pharmanovia |
| Agreement Type | Exclusive partnership (manufacture, development, commercialization) |
| Product | Senaparib (brand: Paishuning), novel PARP1/2 inhibitor |
| Scope | Monotherapy for maintenance treatment of advanced epithelial high‑grade ovarian, fallopian tube, and primary peritoneal cancer |
| Territories | 66 countries, including all 27 EU members, UK, Norway, Iceland, Switzerland, Liechtenstein, Australia, New Zealand, and MENA region |
| Deal Value | Up to EUR 423.5 million (upfront + regulatory and commercialization milestones) |
| Royalties | Tiered, up to mid‑twenties percentage on net product sales |
Product Profile & Regulatory Status
- Molecule: Senaparib, a novel, highly active PARP1/2 inhibitor independently developed by IMPACT Therapeutics.
- Indication: First‑line maintenance treatment of adult patients with advanced ovarian cancer (also covering fallopian tube and primary peritoneal cancer in the licensed scope).
- Regulatory Path: MAA accepted by the EMA in August 2025; approval expected in H2 2026.
- Competitive Positioning: A next‑generation PARP inhibitor entering an established maintenance‑therapy market currently served by olaparib, niraparib, and rucaparib.
Commercial Terms
- Exclusive Rights: IMPACT granted Pharmanovia exclusive rights for the manufacture, development, and commercialization of senaparib as a monotherapy for the specified indication.
- Territory Coverage: 66 countries — all 27 EU member states, plus the UK, Norway, Iceland, Switzerland, Liechtenstein, Australia, New Zealand, and countries across the Middle East and North Africa (MENA) region.
- Payment Structure: IMPACT is eligible to receive total payments of up to EUR 423.5 million, comprising an upfront payment, near‑term regulatory milestone payments, and commercialization milestone payments upon achieving corresponding sales thresholds.
- Royalties: Tiered royalties up to the mid‑twenties percentage based on net product sales.
Market Impact & Outlook
- Ovarian Cancer Maintenance Market: First‑line maintenance PARP therapy has become the standard of care in advanced ovarian cancer, creating a large and durable global market.
- Broad Geographic Reach: Coverage of 66 markets through a single partner positions senaparib for rapid international rollout following the anticipated EMA decision in H2 2026.
- China Biotech Out‑Licensing Signal: The deal — among the larger European out‑licensing agreements for a Chinese‑developed PARP inhibitor — underscores continued global appetite for Chinese oncology assets.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timing, milestone achievement, and commercial expectations for senaparib. Actual results may differ due to risks including the EMA decision, market adoption, and competitive dynamics.-Fineline Info & Tech